4-hydroperoxy Cyclophosphamide (Synonyms: 4-OOH-CY) |
Catalog No.GC42401
One-Click Copy Product Info
|
4-hydroperoxy Cyclophosphamide, métabolite actif du cyclophosphamide, peut réticuler l'ADN et induire l'apoptose des cellules T indépendamment de l'activation du récepteur de la caspase. Il active également la voie de la mort mitochondriale par la production d'espèces réactives de l'oxygène (ROS).
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 39800-16-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
4-hydroperoxy Cyclophosphamide, métabolite actif du cyclophosphamide, peut réticuler l'ADN et induire l'apoptose des cellules T indépendamment de l'activation du récepteur de la caspase. Il active également la voie de la mort mitochondriale par la production d'espèces réactives de l'oxygène (ROS). 4-hydroperoxy Cyclophosphamide est utile dans la recherche sur la polyarthrite rhumatoïde et les maladies auto-immunes[1-2].
4-hydroperoxy Cyclophosphamide (1 μg/ml, 72-96 h), ainsi que le méthotrexate, suppriment l'expression du RANKL dans les synoviocytes de type fibroblaste stimulés par l'IL-6/sIL-6R en inhibant les voies de signalisation JAK2/STAT3 et p38MAPK[3]. Le traitement à 4-hydroperoxy Cyclophosphamide (3 μg/ml ; 48h) a entraîné la production d'espèces réactives de l'oxygène, l'augmentation des niveaux de Bax et la translocation des facteurs mitochondriaux apoptosis-inducing factor (AIF) et endonucléase G (EndoG) vers le noyau. Ce traitement provoque la mort cellulaire indépendante de la caspase chez les CTL humains [4].
4-hydroperoxy Cyclophosphamide (200 mg/kg ; i.p. ; 5 jours) a induit une mort cellulaire indépendante de la caspase dans les cellules T et les cellules B de souris[4]. L'injection intradermique de 4-hydroperoxy Cyclophosphamide (50-200 μg) sur le site sensibilisé dans des modèles de sensibilité au contact in vivo chez le cobaye a entraîné un renforcement significatif de l'hypersensibilité au contact[5].
References:
[1]. Fleer R, Brendel M. Toxicity, interstrand cross-links and DNA fragmentation induced by 'activated' cyclophosphamide in yeast: comparative studies on 4-hydroperoxy-cyclophosphamide, its monofunctional analogon, acrolein, phosphoramide mustard, and nor-nitrogen mustard. Chem Biol Interact. 1982 Mar 1;39(1):1-15. doi: 10.1016/0009-2797(82)90002-3. PMID: 7037214.
[2]. Chen Y, Ai L, et,al. The EZH2-H3K27me3 axis modulates aberrant transcription and apoptosis in cyclophosphamide-induced ovarian granulosa cell injury. Cell Death Discov. 2023 Nov 14;9(1):413. doi: 10.1038/s41420-023-01705-6. PMID: 37963880; PMCID: PMC10646043.
[3]. Niu HQ, Zhao WP, et,al. Combination of 4-hydroperoxy cyclophosphamide and methotrexate inhibits IL-6/sIL-6R-induced RANKL expression in fibroblast-like synoviocytes via suppression of the JAK2/STAT3 and p38MAPK signaling pathway. Int Immunopharmacol. 2018 Aug;61:45-53. doi: 10.1016/j.intimp.2018.05.014. Epub 2018 May 24. PMID: 29803913.
[4]. Strauss G, Westhoff MA, et,al. 4-hydroperoxy-cyclophosphamide mediates caspase-independent T-cell apoptosis involving oxidative stress-induced nuclear relocation of mitochondrial apoptogenic factors AIF and EndoG. Cell Death Differ. 2008 Feb;15(2):332-43. doi: 10.1038/sj.cdd.4402272. Epub 2007 Nov 23. PMID: 18034189.
[5]. Boerrigter GH, de Groot J, et,al. Intradermal administration of 4-hydroperoxy-cyclophosphamide during contact sensitization potentiates effector T cell responsiveness in draining lymph nodes. Immunopharmacology. 1986 Feb;11(1):13-20. doi: 10.1016/0162-3109(86)90060-3. PMID: 3485619.
| Expériences cellulaires [1]: | |
Lignées cellulaires | Cellules T cytotoxiques humaines primaires (CTL) |
Méthode de préparation | Les cellules ont été cultivées en absence (non traitées) ou en présence de 4-hydroperoxy Cyclophosphamide (3 μg/ml) pendant 48 h. |
Conditions de réaction | 3 μg/ml；48h |
Domaines d'application | 4-hydroperoxy Cyclophosphamide induit la mort indépendante de la caspase des lymphocytes T cytotoxiques (CTL) humains après traitement. |
| Expériences animales [2]: | |
Modèles animaux | Souris BALB/c |
Méthode de préparation | Les souris ont reçu une injection i.p. de 200 mg/kg de 4-hydroperoxy Cyclophosphamide. |
Forme de dosage | 200 mg/kg ; i.p. ; 5 jours |
Domaines d'application | Le traitement à 4-hydroperoxy Cyclophosphamide induit une mort indépendante de la caspase dans les cellules T et les cellules B de la souris. |
Références : | |
| Cas No. | 39800-16-3 | SDF | |
| Synonymes | 4-OOH-CY | ||
| Chemical Name | 2-[bis(2-chloroethyl)amino]tetrahydro-2-oxido-2H-1,3,2-oxazaphosphorin-4-yl, hydroperoxide | ||
| Canonical SMILES | O=P1(N(CCCl)CCCl)OCCC(OO)N1 | ||
| Formula | C7H15Cl2N2O4P | M.Wt | 293.1 |
| Solubility | DMSO : 50 mg/mL (170.60 mM; Need ultrasonic) | Storage | -80°C |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 3.4118 mL | 17.059 mL | 34.118 mL |
| 5 mM | 682.4 μL | 3.4118 mL | 6.8236 mL |
| 10 mM | 341.2 μL | 1.7059 mL | 3.4118 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >95.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 21 reference(s) in Google Scholar.)